N/A
Manufactured by Sumitomo Pharma America, Inc.
41,710 FDA adverse event reports analyzed
Last updated: 2026-04-14
LURASIDONE HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Sumitomo Pharma America, Inc.. The most commonly reported adverse reactions for LURASIDONE HYDROCHLORIDE include OFF LABEL USE, DRUG INEFFECTIVE, ANXIETY, FEELING ABNORMAL, DEPRESSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LURASIDONE HYDROCHLORIDE.
Out of 20,541 classified reports for LURASIDONE HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 41,710 FDA FAERS reports that mention LURASIDONE HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include OFF LABEL USE, DRUG INEFFECTIVE, ANXIETY, FEELING ABNORMAL, DEPRESSION, WEIGHT INCREASED. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Sumitomo Pharma America, Inc. in connection with LURASIDONE HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.